Diabetes Care, Vol 17, Issue 6 541-547, Copyright © 1994 by American Diabetes Association
Evaluation of the costs to Medicare of covering therapeutic shoes for diabetic patients
J Wooldridge and L Moreno
Mathematica Policy Research, Princeton, New Jersey 08543-2393.
OBJECTIVE--A three-year demonstration was fielded in three states to
evaluate the cost to Medicare of a therapeutic shoes benefit for Medicare
Part B beneficiaries with severe diabetic foot disease. RESEARCH DESIGN AND
METHODS--Eligible Medicare beneficiaries who applied were randomly assigned
to either a treatment group that received the extra therapeutic shoe
coverage or a control group that received only standard Medicare coverage.
This study analyzes the Medicare payments and service use of 3,428
demonstration participants in California, Florida, and New York for whom
data on a 12-month follow-up period were available. These results are
comparable to those for the entire sample over a variable length follow-up
period that averaged 20 months but ranged from 3 months to 3 years.
RESULTS--Differences between groups are not statistically significant.
However, Medicare payments for all services among the treatment group were
$451 (3.8%) higher than those for all services among the control group.
Similarly, Medicare payments for foot-care services were $318 (14.6%)
higher among beneficiaries in the treatment group, which considerably
exceeded the cost of the shoe benefit ($118). CONCLUSIONS--The
demonstration produced no definitive evidence that expanding Medicare Part
B to cover therapeutic shoes for beneficiaries with severe diabetic foot
disease would increase total Medicare costs. However, our findings indicate
that the demonstration was successful at increasing therapeutic shoe
ownership and was instrumental in increasing beneficiaries' use of the
shoes when walking outdoors.